AZUR-1 delivers. #ESMO26 Phase 2, single arm. Dostarlimab x 9 cycles (6 months) in untreated stage II/III dMMR/MSI-H rectal cancer, 154 patients. Cercek's 49-patient NEJM cohort gone global. No control arm, because randomizing these patients to TNT/TME isn't equitable. cCR12 (complete response held 12+ months, no further treatment):
68% by investigator. 

26% needed additional treatment
10% went to surgery 68% is likely lower than reality since many patients probably just needed more time to radiographically respond. Using PET/Biopsy/ctDNA, especially ctDNA, is incredibly helpful in my practice to identify patients who can avoid TME even if a fibrotic tumor remains as they often do. FDA already gave accelerated approval (way to steal the ESMO thunder) last week which leads me to my next point. Obvious new standard of care. You should go to oncology jail if you don't treat MSI-H with IO. @OncoAlert @TheGutOncLab @Onco_Nexus